Health Care & Hospital Law
Mar. 23, 2011
Biotechs End Drug Development Agreement
Depomed Inc., a Menlo Park-based biotechnology firm, announced in a document filed recently with the Securities and Exchange Commission that it received $40 million and regained the North American rights to its drug Gralise.
Daily Journal Staff Writer
Depomed Inc., a Menlo Park-based biotechnology firm, announced in a document filed recently with the Securities and Exchange Commission that it received $40 million and regained the North American rights to its drug Gralise.
The settlement with Abbott Laboratories ended a drug development and commercialization agreement for the drug, which was approved by the U.S. Food and Drug Administration in Janu...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In